Arbitrators cleared the way for the long-delayed $53 billion acquisition after Exxon tried to pre-empt the deal. 3M raised its full-year earnings outlook after beating expectations in the second ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL patients who are not eligible for autologous stem cell transplant, Roche ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Despite the setback with the Oncologic Drugs Advisory Committee vote, GSK emphasizes the unmet need in multiple myeloma and ...

The U.S. FDA has approved a prefilled syringe presentation of GSK plc’s SHINGRIX for the prevention of shingles.

GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

London stocks ended higher on Friday, supported by a positive shift in investor sentiment following US consumer confidence ...

European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...